ArticleFrontiers in neuroscience2026
Stabilizing effects of geraniol on native and pathogenic M39R rhodopsin variants.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mutations in rhodopsin are a major cause of autosomal dominant retinitis pigmentosa, frequently due to protein misfolding and reduced structural stability. The M39 Methods: We investigated whether geraniol, a natural monoterpenoid alcohol with reported cytoprotective properties, can act as a pharmacological stabilizer of rhodopsin. Using purified pigments from bovine rod outer segments and recombinant wild-type and M39 Results: Geraniol did not interfere with chromophore binding, photobleaching, regeneration, or acid-induced Schiff base protonation. However, it significantly enhanced the thermal and chemical stability of rod outer segments-derived and recombinant wild-type rhodopsin. The M39 Discussion: These findings identify geraniol as a membrane-interacting small molecule capable of partially stabilizing structurally compromised rhodopsin variants. While incomplete, the rescue achieved supports the potential of monoterpenoid-based pharmacological chaperones for selected rhodopsin-linked retinal degenerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.